CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
在真实世界多种族队列中，LDH 升高大于 400 U/L 预示接受 CD19 CAR-T 细胞治疗的弥漫大 B 细胞淋巴瘤患者总生存期更差
英文原题：Elevated LDH greater than 400 U/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort.
查看英文原题
Elevated LDH greater than 400 U/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
抗 CD19 CAR-T 细胞疗法在弥漫大 B 细胞淋巴瘤中显示出显著的临床活性，但仍需要能预测治疗反应的稳健生物标志物。我们以 axicabtagene ciloleucel 治疗了一个由 31 例弥漫大 B 细胞淋巴瘤患者组成的多种族队列，总缓解率为 71%。对多种生物标志物的分析发现，在细胞输注时和淋巴细胞清除前测得的乳酸脱氢酶升高与总生存期显著缩短相关。乳酸脱氢酶在多变量分析中具有预后意义 [HR = 1.47 (1.1-2.0)]，在我们的队列中，输注时 400 U/L 和淋巴细胞清除前 440 U/L 的数值为总生存期提供了最佳预后截断值。这些数据证明抗 CD19 CAR-T 细胞疗法在多元化的城市中心人群中有效，并证明新的乳酸脱氢酶截断值可作为预后生物标志物。
展开英文摘要原文
Anti-CD19 chimeric antigen receptor T-cell therapies have shown striking clinical activity in diffuse large B-cell lymphoma but robust biomarkers predictive of responsiveness are still needed.
We treated a multi-ethnic cohort of 31 diffuse large B-cell lymphoma patients with axicabtagene ciloleucel with an overall response rate of 71%. Analysis of various biomarkers identified a significant decrease in overall survival with elevated lactate dehydrogenase, measured both at time of cell infusion and before lymphodepletion. Lactate dehydrogenase was prognostic in a multivariate analysis [HR = 1.
47 (1. 1-2. 0)] and a value of 400 U/L at time of infusion and a value of 440 U/L before lymphodepletion provided the best prognostic cutoffs for overall survival in our cohort. These data demonstrate efficacy of anti-CD19 chimeric antigen receptor T-cell therapy in a diverse inner city population and demonstrate novel lactate dehydrogenase cutoffs as prognostic biomarkers.
论文信息
- 作者
- Rabinovich E、Pradhan K、Sica RA、Bachier-Rodriguez L、Mantzaris I、Kornblum N、Shastri A、Gritsman K
- 第一作者单位
- Department of Oncology, Montefiore Medical Center, Bronx, NY, 10461, USA.United States
- 通讯作者单位
- Department of Oncology, Montefiore Medical Center, Bronx, NY, 10461, USA. ibraunsc@montefiore.org.United States
- 文献类型
- 读者来信
- 期刊
- Experimental hematology & oncology2021 Dec 9
- 原文标识
- PubMed 34886908 · DOI 10.1186/s40164-021-00248-9
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →